Treatment with GLP-1 receptor agonists after bariatric surgery was associated with a significantly lower risk of alcohol use disorder (AUD) compared with patients without this treatment, according to the article[1]. Patients treated with incretins were also less likely to start AUD treatment after surgery[1]. The study reports specific percentage risk reductions (reported in the article as significant), with differences between groups persisting after adjusting for demographic and clinical factors[1]. The analysis included patients after different types of bariatric surgery, and the effect of incretin treatment was consistent across subgroups[1]. The authors noted that the findings were observable and based on a comparative analysis between treated and untreated groups[1]. The article does not state that incretin treatment directly causes a reduction in AUD - it describes an association based on the available data[1].